Answers are grounded in this paper and cite their sources.
Meta-analysis evaluates glucagon-like peptide 1 receptor agonists' effects on revascularization and amputation in diabetes with peripheral arterial disease, indicating no significant differences.
In this meta-analysis of randomized trials, GLP-1 RAs were not associated with statistically significant differences in revascularization or amputation outcomes in individuals with diabetes and PAD.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: